Alpha Anomeric

Novel oligonucleotide chemistry platform for inherited genetic diseases

Alpha Anomeric is using a novel, proprietary oligonucleotide chemistry platform for the design of a new class of RNA modulating oligonucleotides. These will be evaluated for the treatment of various inherited genetic diseases.

CEO  Wolfgang Renner

Advent Contact Dominic Schmidt

Advent co-founded Alpha Anomeric in 2018 and was the sole investor in the Series A.
Private Companies